Association of Proton Pump Inhibitor Use with Cancer in Patients Undergoing Maintenance Hemodialysis: A Population-Based Cohort Study
Abstract
Background: Despite widespread proton pump inhibitor (PPI) use in hemodialysis (HD), evidence on cancer risk in high-risk populations remains scarce. We investigated the association between PPI use and incident cancer in a population-based cohort of patients receiving HD. Methods: We used data from the 4th–7th HD quality assessments from South Korea and data linked to claims and death. We classified patients by PPI prescription over 1 year, including No-Prescription (no PPI during the year, n = 37,934); Short (PPI for <60 days, n = 9909); and Long (PPI for ≥60 days, n = 18,108) groups. Any cancer-free survival and overall survival by PPI use were evaluated. Results: The 5-year cancer-free rates for any cancer were 89.6%, 88.5%, and 88.1% in the No-Prescription, Short, and Long groups, respectively. The 5-year patient survival rate was 42.2%, 43.8%, and 40.3% in the No-Prescription, Short, and Long groups, respectively. Patients prescribed PPI had a higher cancer risk than those without a PPI prescription. However, survival among patients with cancer did not differ significantly across the three groups. The Long group had a higher risk of pancreatic and renal cancers than the other two groups. The No-Prescription group had lower risks of thyroid, prostate, and liver cancers than the other groups. Conclusions: In our study, long-term PPI use was associated with higher overall cancer risk, particularly pancreatic and renal cancers, compared with the No-Prescription group.…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 37,934 participants or records.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.